Zhitong Finance App News, Yingen Bio-B (09606.HK) announced that on August 27, 2026, the company signed a cooperation and license agreement (cooperation agreement) with Genentech, Inc. (Genentech), a member company of the Roche Group, to develop next-generation antibody-conjugated drugs (ADC) for several tumor indications based on the company's proprietary Yingen unique payload antibody conjugation (DUPAC) platform. According to the terms of the cooperation agreement, the company will lead the discovery and early global clinical development of cooperative projects. Genentech will obtain an exclusive global license for the ADC generated by the collaboration, and after phase 1a clinical development is completed, Genentech will assume sole responsibility for further clinical development and commercialization.

Zhitong Finance App News, Yingen Bio-B (09606.HK) announced that on August 27, 2026, the company signed a cooperation and license agreement (cooperation agreement) with Genentech, Inc. (Genentech), a member company of the Roche Group, to develop next-generation antibody-conjugated drugs (ADC) for several tumor indications based on the company's proprietary Yingen unique payload antibody conjugation (DUPAC) platform. According to the terms of the cooperation agreement, the company will lead the discovery and early global clinical development of cooperative projects. Genentech will obtain an exclusive global license for the ADC generated by the collaboration, and after phase 1a clinical development is completed, Genentech will assume sole responsibility for further clinical development and commercialization.